Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThermoDox with radiotherapy and hyperthermia for locoregional relapse in breast cancer
2015-000167-14Phase 2Terminated
- Sponsor
- Imunon, Inc.
- Start
- May 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in breast cancer, sponsored by Imunon, Inc. Primary endpoint: Objective tumor response. Started May 2021; status: terminated.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-000167-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000167-14.